Astrazeneca (AZN) Operating Margin Growth (3y) (2012 - 2026)
Astrazeneca (AZN) Operating Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Operating Margin Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
10.00 |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
2,500.00 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-91.00 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
395.00 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-4,555.00 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-53.00 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
1,031.00 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-9,003.00 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
-338.00 |
| 10 |
Astrazeneca |
72.15 Bn |
64.21 Bn |
12.61 Bn |
-392,646.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
-392,646.00 |
| Dec 31, 2025 |
4.89 Mn |
| Sep 30, 2025 |
3.19 Mn |
| Jun 30, 2025 |
2.59 Mn |
| Mar 31, 2025 |
462,455.00 |
| Dec 31, 2024 |
30,674.00 |
| Sep 30, 2024 |
490,869.00 |
| Jun 30, 2024 |
6.80 Mn |
| Mar 31, 2024 |
454,565.00 |
| Dec 31, 2023 |
7,281.00 |
| Sep 30, 2023 |
-453.00 |
| Jun 30, 2023 |
70,690.00 |
| Mar 31, 2023 |
660,353.00 |
| Dec 31, 2022 |
18,540.00 |
| Sep 30, 2022 |
42,316.00 |
| Jun 30, 2022 |
1.75 Mn |
| Mar 31, 2022 |
-387,892.00 |
| Dec 31, 2021 |
-32,658.00 |
| Sep 30, 2021 |
-248,920.00 |
| Jun 30, 2021 |
3,360.00 |
